We know you by name and treat you like family, ensuring you get the best advice and attention
Semaglutide is a synthetic version of a naturally occurring hormone that acts on appetite centers in the brain and in the gut, producing feelings of satiety
This has led to conceptualizing obesity as a chronic disease requiring ongoing management rather than a condition amenable to short-term cure
Van Raalte Frontiers in Endocrinology doi 10.3389/fendo.2021.645563 435,236 views 325 citations Original Research Published on 02 Jun 2025 Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice in Gastrointestinal and Hepatic Pharmacology Luyan Sun Bingqing Shang Suyuan Lv Guolong Liu Qiu Wu Yue Geng Frontiers in Pharmacology doi 10.3389/fphar.2025.1562896 12,733 views 30 citations Original Research Published on 10 Mar 2025 Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/-catenin signaling pathway in Experimental Pharmacology and Drug Discovery Yawei Tian Huiming Liu Xiaoxue Bao Yukun Li Frontiers in Pharmacology doi 10.3389/fphar.2025.1539411 9,310 views 18 citations Original Research Published on 09 Dec 2022 Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model in Obesity Shu Niu Shuchun Chen Xing Chen Qingjuan Ren Lin Yue Xiaoyu Pan Huiying Zhao Zelin Li Xiaoyi Chen Frontiers in Endocrinology doi 10.3389/fendo.2022.1046130 39,754 views 69 citations Systematic Review Published on 06 Oct 2021 Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis in Drugs Outcomes Research and Policies Ping Zhong Hai Zeng Miaochun Huang Guoxin He Zhixia Chen Frontiers in Pharmacology doi 10.3389/fphar.2021.695182 15,518 views 21 citations Systematic Review Published on 05 Jul 2024 Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis in Clinical and Translational Cardiovascular Medicine Walter Masson Martn Lobo Juan Patricio Nogueira Alfredo Matias Rodriguez-Granillo Leandro Ezequiel Barbagelata Daniel Siniawski Frontiers in Cardiovascular Medicine doi 10.3389/fcvm.2024.1379189 19,786 views 51 citations Review Published on 28 Aug 2023 Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review in Obesity Zeyu Xie Jia Hu Hangye Gu Mengting Li Jisheng Chen Frontiers in Endocrinology doi 10.3389/fendo.2023.1244432 27,816 views 47 citations Review Published on 29 Jun 2021 Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide in Clinical Diabetes Baptist Gallwitz Francesco Giorgino Frontiers in Endocrinology doi 10.3389/fendo.2021.645507 37,001 views 71 citations Original Research Published on 07 Oct 2024 SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice in Renal Pharmacology Nerea Martos-Guillami Ander Vergara Carmen Llorens-Cebri Aku Enam Motto Irene Martnez-Daz Francisco Gonalves Maria Magdalena Garcias-Ramis Estibaliz Allo-Urzainqui Alonso Narvez Sheila Bermejo Frontiers in Pharmacology doi 10.3389/fphar.2024.1415879 7,359 views 10 citations Case Report Published on 21 Jan 2025 Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review in Obesity Andrijana Koceva Katarina Mleku Kozamernik Andrej Jane Rok Herman Simona Ferjan Mojca Jensterle Frontiers in Endocrinology doi 10.3389/fendo.2024.1528457 14,451 views 6 citations
Schaefer C, Ornoy A, Clementi M, et al
)
